These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22879932)

  • 1. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.
    Gong R; Wang Y; Ying T; Dimitrov DS
    PLoS One; 2012; 7(8):e42288. PubMed ID: 22879932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A large human domain antibody library combining heavy and light chain CDR3 diversity.
    Chen W; Zhu Z; Feng Y; Dimitrov DS
    Mol Immunol; 2010 Jan; 47(4):912-21. PubMed ID: 19883941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor.
    Gong R; Wang Y; Feng Y; Zhao Q; Dimitrov DS
    J Biol Chem; 2011 Aug; 286(31):27288-93. PubMed ID: 21669873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and screening of IgG binding to the neonatal Fc receptor.
    Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
    MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.
    Wang Y; Kapoor P; Parks R; Silva-Sanchez A; Alam SM; Verkoczy L; Liao HX; Zhuang Y; Burrows P; Levinson M; Elgavish A; Cui X; Haynes BF; Schroeder H
    Immunogenetics; 2016 Feb; 68(2):145-55. PubMed ID: 26687685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
    Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
    J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
    Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
    J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
    Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
    Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain.
    Chen W; Zhu Z; Feng Y; Xiao X; Dimitrov DS
    J Mol Biol; 2008 Oct; 382(3):779-89. PubMed ID: 18687338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
    Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
    J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics.
    Ching KH; Berg K; Reynolds K; Pedersen D; Macias A; Abdiche YN; Harriman WD; Leighton PA
    MAbs; 2021; 13(1):1862451. PubMed ID: 33491549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies.
    Fernández-Quintero ML; Kroell KB; Grunewald LJ; Fischer AM; Riccabona JR; Liedl KR
    MAbs; 2022; 14(1):2024118. PubMed ID: 35090383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel heavy domain antibody library with functionally optimized complementarity determining regions.
    Mandrup OA; Friis NA; Lykkemark S; Just J; Kristensen P
    PLoS One; 2013; 8(10):e76834. PubMed ID: 24116173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding.
    Cao G; Gao X; Zhan Y; Wang Q; Zhang Z; Dimitrov DS; Gong R
    MAbs; 2020; 12(1):1689027. PubMed ID: 31795802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors.
    Xiao X; Feng Y; Vu BK; Ishima R; Dimitrov DS
    Biochem Biophys Res Commun; 2009 Sep; 387(2):387-92. PubMed ID: 19615335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.
    Chen W; Bardhi A; Feng Y; Wang Y; Qi Q; Li W; Zhu Z; Dyba MA; Ying T; Jiang S; Goldstein H; Dimitrov DS
    MAbs; 2016; 8(4):761-74. PubMed ID: 26963639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.
    Townsend S; Fennell BJ; Apgar JR; Lambert M; McDonnell B; Grant J; Wade J; Franklin E; Foy N; Ní Shúilleabháin D; Fields C; Darmanin-Sheehan A; King A; Paulsen JE; Hickling TP; Tchistiakova L; Cunningham O; Finlay WJ
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15354-9. PubMed ID: 26621728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.